MANE

Veradermics, Incorporated

NYSE: MANE · HEALTHCARE · BIOTECHNOLOGY

$106.07

-1.47% today

Updated 2026-06-03

Market cap

$3.83B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.65

Dividend yield

—

52W range

$32 – $118

Volume

0.6M

Market cap

$3.83B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.65

Dividend yield

—

52W range

$32 – $118

Volume

0.6M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.0

Quality

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$132.25

+24.68%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Piotroski 3/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-21.17M

Key financials

Revenue Net Income Free Cash Flow

Metric	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00
Net income	$-16.49M	$-26.49M	$-70.00M	$-27.23M
EPS	—	—	—	$-2.65
Free cash flow	$-13.51M	$-23.69M	$-71.63M	$-21.17M
Profit margin	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
MANE	$3.83B	25	4.3	3.0	5.0	6.0	—	Avoid
LLY	$948.95B	78	10.0	10.0	5.0	6.0	—	Strong Buy
JNJ	$536.54B	59	4.7	9.0	3.3	6.0	-71.41%	Buy
ABBV	$380.57B	63	4.0	8.0	4.0	5.0	-55.64%	Buy
UNH	$343.21B	54	5.3	5.5	4.7	5.5	-26.61%	Buy
MRK	$285.64B	50	3.3	8.0	2.7	5.0	-49.34%	Hold

Smart narrative

Veradermics, Incorporated trades at $106.07. Our Smart Value Score of 25/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score.

Frequently asked questions

What is Veradermics, Incorporated's stock price?

Veradermics, Incorporated (MANE) trades at $106.07.

Is Veradermics, Incorporated overvalued?

Veradermics, Incorporated carries a Smart Value Score of 25/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Veradermics, Incorporated (MANE)?

The 12-month analyst consensus target is $132.25, about 24.7% above the current $106.07. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNYSE

CurrencyUSD

Quick metrics

P/S ratio—

ROE-72.10%

Beta—

50D MA$86.84

200D MA$71.36

Shares out0.04B

Float0.03B

Short ratio—

Avg volume0.6M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

MANE vs LLY →MANE vs JNJ →MANE vs ABBV →Stock screener →